Metabolic & Weight

Incretin research pens, GLP-1, GIP and glucagon agonists studied for metabolic and weight research.

Retatrutide 20 mg research peptide click pen, front of box, Veyvora

3 mL pen · A triple GLP-1 / GIP / glucagon agonist in a pre-filled 3 mL click pen. The 20 mg pen for metabolic research.

metabolic

Retatrutide 40

3 mL pen · The high-capacity 40 mg Retatrutide pen, same triple-agonist molecule, double the clicks of active per pen.

metabolic

Tirzepatide 40

3 mL pen · Dual GIP / GLP-1 agonist in a 40 mg click pen, studied for metabolic and weight research.

Dosierungsleitfäden für diese Kategorie:Retatrutide 40·Tirzepatide 40

the incretin class, in research terms

The metabolic range acts on the receptors for the body’s incretin signalling system — chiefly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), and, in the newest compounds, the glucagon receptor. These receptor systems are central to metabolic and energy-balance research, which is why single-, dual- and triple-agonist peptides are among the most actively studied compounds in the field.

Every pen in this range is supplied for laboratory research use only, independently assayed, and shipped with a batch-specific certificate of analysis.

why the agonist profile is the axis of comparison

A metabolic peptide is defined, more than anything else, by which receptors it activates — its agonist profile. That single property is what researchers compare compounds on:

GLP-1 receptor — the most-studied incretin target in glucose-regulation and appetite-signalling research.
GIP receptor — a second incretin target; co-agonism with GLP-1 is the basis of the “dual agonist” generation.
Glucagon receptor — studied in energy-expenditure and hepatic-metabolism contexts; adding it produces the newer “triple agonist” compounds.

More receptors engaged does not mean “better” — it means a different research profile. The right compound depends on the pathway under study.

the compounds in this range

Tirzepatide — a dual GIP / GLP-1 receptor agonist, and the reference compound for co-agonist research.
Retatrutide (also available as Retatrutide 20) — a triple GIP / GLP-1 / glucagon agonist representing the newest generation.

For a direct, criteria-matched comparison of the two, see Retatrutide vs Tirzepatide.

verifying identity and purity

Underdosed and mislabelled product is the central problem in this market, and it matters most for high-potency metabolic compounds. Every metabolic pen ships with an independent certificate of analysis tied to its batch number, reporting identity and HPLC purity — so the compound can be checked before any research use begins, rather than taken on a supplier’s word. See how to read a COA.

research use only

These compounds are supplied strictly for in-vitro and laboratory research. They are not medicines, are not for human or veterinary consumption, and nothing here is dosing, medical, or treatment guidance.

bündeln & sparen